Entyvio (vedolizumab) prior authorization denied appeal
Integrin inhibitor for UC and Crohn's
Typical PA criteria
- UC or Crohn's disease diagnosis (ICD-10 K51.x or K50.x)
- Prior anti-TNF trial or contraindication
- Gastroenterologist prescriber
- TB/HBV screening
Why your PA was denied
- Anti-TNF step therapy not completed
- Non-gastroenterology prescriber
- Screening absent
- Baseline disease activity not documented
Evidence that overturns the denial
- ✓HBI or partial Mayo score at baseline
- ✓Prior anti-TNF trial with dose, duration, TDM if available
- ✓Gastroenterology letter
- ✓Screening labs
Gut-selective mechanism; preferred in patients with anti-TNF failure or infection risk. Reauthorization requires documented clinical response.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Entyvio (vedolizumab) prior authorization denied?+
The most common reasons are: Anti-TNF step therapy not completed; Non-gastroenterology prescriber; Screening absent. Your denial letter names the specific criteria you did not meet.
How do I appeal a Entyvio (vedolizumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Entyvio (vedolizumab) denial?+
HBI or partial Mayo score at baseline; Prior anti-TNF trial with dose, duration, TDM if available; Gastroenterology letter.
What if the plan excludes Entyvio (vedolizumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)